Skip to main content
An official website of the United States government


Placeholder slot

Atezolizumab is a type of targeted therapy drug called an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Atezolizumab is approved to be used alone or with other drugs to treat:

Atezolizumab is also being studied in the treatment of other types of cancer.

More About Atezolizumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Atezolizumab - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Trial Results Confirm Effectiveness of Atezolizumab Against a Rare Sarcoma

Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects

Targeted Cancer Therapies

Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why

Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer

Monoclonal Antibodies

Immune Checkpoint Inhibitors

Clinical Trials Accepting Patients

Find Clinical Trials for Atezolizumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: